Picard Medical / SynCardia to Participate in Inaugural "Hands-On Training Day" at the Technology and Heart Failure Therapeutics Conference
MWN-AI** Summary
Picard Medical, Inc. (NYSE American: PMI), the parent company of SynCardia Systems LLC, has announced its participation in the inaugural "Hands-On Training Day" at the Technology and Heart Failure Therapeutics (THT) 2026 conference on March 1, 2026, in Boston. Picard Medical, known for manufacturing the SynCardia Total Artificial Heart, the first device of its kind approved by both the U.S. FDA and Health Canada, is enthusiastic about this interactive program aimed at enhancing clinician education regarding mechanical circulatory support and the management of advanced heart failure.
Stephen Zamojski, Head of Global Sales and Clinical Education at SynCardia, emphasized the importance of education and hands-on experience as the adoption of total artificial heart therapy grows. The training day's structure promotes collaboration among medical professionals, allowing them to deepen their understanding of how the SynCardia Total Artificial Heart functions in severe heart failure scenarios. The recent success of the SynCardia Training Village in Houston reflects the company’s commitment to expanding clinical partnerships and raising awareness about their innovative heart technology.
During the training, participants will engage directly with both the Companion 2 Driver and the Freedom Portable Driver, alongside the SynCardia Total Artificial Heart. Led by Senior Clinical Specialists Lauren Wallace and Skyler Peffly, the session will feature interactive stations fostering focused instruction, peer exchange, and problem-solving, tailored to real-world clinical scenarios.
The THT conference serves as an international platform for advancing heart failure therapies, emphasizing innovation through collaboration among clinicians, researchers, and industry stakeholders. Through participation in such initiatives, Picard Medical aims to facilitate improved outcomes for patients suffering from advanced heart failure, reinforcing its status as a leading entity in the medical device industry. For more information on Picard Medical, visit their website or review their filings with the SEC.
MWN-AI** Analysis
**Market Analysis and Investment Considerations for Picard Medical / SynCardia**
Picard Medical, Inc. (NYSE American: PMI), through its subsidiary SynCardia Systems LLC, is positioning itself as a leader in the heart failure space with the only FDA and Health Canada-approved total artificial heart. The company is making strategic moves by participating in advanced training initiatives, exemplified by their involvement in the inaugural Hands-On Training Day at the Technology and Heart Failure Therapeutics (THT) 2026 conference in Boston.
This event underscores several key elements beneficial for investors. Firstly, it highlights SynCardia's commitment to education and clinical engagement, crucial for widespread adoption of its life-saving technology. By fostering direct interaction with healthcare professionals, the company not only drives awareness but also increases the proficiency with which new users can deploy its technology. The hands-on training approach reflects a strategic focus on collaboration and community within the medical field, which is likely to enhance its product’s market penetration.
Moreover, with over 2,100 successful implants performed across 27 countries, SynCardia’s track record establishes a level of trust and reliability. As healthcare systems globally emphasize the importance of advanced heart failure management, the demand for effective technologies such as the SynCardia Total Artificial Heart is likely to continue to grow.
From a market perspective, this could translate into strong revenue potential as healthcare providers increasingly integrate these solutions into their practices. However, investors should remain aware of risks, particularly regulatory hurdles and the inherent uncertainties in any innovation-driven sector.
In conclusion, while the stock may present a promising opportunity due to its unique positioning and ongoing industry engagement, a cautious approach is advised. Keeping abreast of regulation-related risks, pricing pressures, and market competition will be essential for making informed investment decisions in PMI moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TUCSON, Ariz., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the inaugural “Hands-On Training Day” at the Technology and Heart Failure Therapeutics (THT) 2026 conference to be held in Boston on March 1st 2026.
This interactive, case-based program hosted for the first time at the conference will bring together leading clinicians and innovators to advance education in temporary and durable mechanical circulatory support, hemodynamic monitoring, and the management of cardiogenic shock. Through hands-on training and real-world clinical scenarios, the program is designed to strengthen multidisciplinary collaboration among practitioners and improve patient outcomes in advanced heart failure.
Stephen Zamojski, Head of Global Sales and Clinical Education at SynCardia Systems LLC, commented, “As adoption of total artificial heart therapy continues to expand, education and hands-on familiarity are critical. By engaging directly with the technology in a collaborative setting, clinicians can deepen their understanding of how the SynCardia Total Artificial Heart supports patients through the most advanced stages of heart failure. Our participation in the inaugural Hands-On Training Day at THT 2026 follows the successful SynCardia Training Village held in Houston earlier this week and reflects a key component of our commercial expansion strategy. We remain focused on building strong clinical partnerships, expanding global awareness, and ensuring that leading heart failure centers are equipped to deliver this life-saving therapy.”
Picard Medical / SynCardia is proud to support this important educational initiative and looks forward to engaging with physicians, fellows, and multidisciplinary clinical teams as it continues to expand global awareness and adoption of total artificial heart therapy. Senior Clinical Specialists, Lauren Wallace, and Skyler Peffly, will lead the training, offering participants direct, hands-on interaction with the Companion 2 Driver, the Freedom Portable Driver, and the SynCardia Total Artificial Heart.
Attendees will rotate through interactive stations in a small group setting designed to foster focused instruction, peer exchange, and active problem solving. The session will incorporate real-world clinical scenarios and guided discussion to support clinical decision-making, device management, and patient care best practices in complex cases of advanced biventricular heart failure.
About THT 2026
Technology and Heart Failure Therapeutics (THT) 2026 is an international conference focused on advancing innovation in heart failure through emerging device, technology, and combination therapies. Sponsored by the Cardiovascular Research Foundation, THT brings together leading clinicians, researchers, and industry partners to share the latest clinical data, discuss regulatory and commercial pathways, and explore future trends shaping the management of advanced heart failure. The multidisciplinary program features cutting- edge scientific sessions, case-based discussions, and hands-on training designed to foster collaboration and improve patient outcomes. For more information, visit https://www.thtmeeting.com/about-tht.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ**
How does Picard Medical Inc. PMI plan to leverage the Hands-On Training Day at THT 2026 to enhance its market presence in the field of mechanical circulatory support?
In what ways will Picard Medical Inc. PMI measure the educational impact of its participation in THT 20on clinicians' understanding of total artificial heart therapy?
What are the strategic goals for Picard Medical Inc. PMI following the Hands-On Training Day at THT 2026 regarding its global sales and clinical partnerships?
How does Picard Medical Inc. PMI ensure the ongoing development and support of healthcare professionals using the SynCardia Total Artificial Heart post-training at conferences like THT 2026?
**MWN-AI FAQ is based on asking OpenAI questions about Picard Medical Inc. (NYSE: PMI).
NASDAQ: PMI
PMI Trading
-1.48% G/L:
$1.1872 Last:
40,526 Volume:
$1.21 Open:
